Sutro Biopharma

Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company. The company focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
  • TickerSTRO
  • ISINUS8693671021
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

David Nierengarten ...
  • Jeffrey La Rosa

1Q19; Coming Up on Initial Clinical Data from the XpressCF Platform

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

ValuEngine Rating and Forecast Report for STRO

ResearchPool Subscriptions

Get the most out of your insights

Get in touch